CN113975302A - Guangdong cordyceps sinensis medicinal liquor for reducing uric acid and preparation method and application thereof - Google Patents
Guangdong cordyceps sinensis medicinal liquor for reducing uric acid and preparation method and application thereof Download PDFInfo
- Publication number
- CN113975302A CN113975302A CN202111288108.1A CN202111288108A CN113975302A CN 113975302 A CN113975302 A CN 113975302A CN 202111288108 A CN202111288108 A CN 202111288108A CN 113975302 A CN113975302 A CN 113975302A
- Authority
- CN
- China
- Prior art keywords
- weight
- uric acid
- parts
- cordyceps
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses Guangdong cordyceps sinensis medicinal liquor for reducing uric acid and a preparation method and application thereof, belonging to the technical field of traditional Chinese medicines. The invention provides Guangdong cordyceps medicinal liquor with the effect of reducing uric acid by taking Guangdong cordyceps as a raw material, which is prepared from 15 parts by weight of Guangdong cordyceps sporophore powder, 3 parts by weight of pilose antler blood powder and 1500 parts by weight of white spirit. Placing the Cordyceps guangdongensis fruiting body powder and cornu Cervi Pantotrichum blood powder in a sterilized container, adding Chinese liquor, sealing the container, and storing for one month. The results of animal experiments show that the effect of reducing uric acid is close to that of a clinical medicine allopurinol tablet. The medicinal liquor has good development and utilization prospects.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and in particular relates to Guangdong cordyceps sinensis medicinal liquor for reducing uric acid and a preparation method and application thereof.
Background
With the continuous improvement of living standard of people, hyperuricemia or gout and other diseases are easily caused by hyperuricemia caused by improper diet and disturbance of metabolic function of kidney. Gout is acute and chronic inflammation and tissue injury caused by deposition of mono-natriuretic urate on bone joints, kidneys, subcutaneous parts and the like, and is directly related to hyperuricemia caused by purine metabolic disorder and/or reduction of uric acid excretion. The gout is a common and complex arthritis disease, all age groups can get ill, according to epidemiological investigation, the prevalence rate of gout arthritis in China is about 1% -3%, and the incidence rate of men is higher than that of women. Gout can be complicated with kidney disease, and severe cases can cause joint destruction and renal function damage, often accompanied with hyperlipidemia, hypertension, diabetes, arteriosclerosis, coronary heart disease, etc. In recent years, the incidence of gout is on the rise, and the population suffering from gout is gradually younger. Therefore, the prevention and treatment of gout has become a hot problem in disease research, and the key point is how to reduce the content of blood uric acid.
At present, gout treatment medicines are used relatively less, and diet adjustment is relatively more. Cordyceps guangdongensis (Cordyceps guangdongensis) is a fungus which is safe to eat and use as a medicine, is approved as a new resource food by the national ministry of health in 2013, and has rich nutrient components and a plurality of remarkable active effects. At present, the research on the effect of the compound on reducing uric acid is not reported. Therefore, research on the effect of reducing uric acid and research and development of related products can provide ideas for research and development of safe and effective dietary supplements, health-care foods, medical intermediates and natural medicines for preventing and treating hyperuricemia and gout, and the method has good economic value and social benefit.
Disclosure of Invention
The invention aims to provide Cordyceps guangdongensis (cordyces guangdongensis) medicinal liquor with the effect of reducing uric acid, which consists of Cordyceps guangdongensis fruiting body powder, pilose antler blood powder and white spirit.
Preferably, 15 parts of cordyceps guangdongensis sporocarp powder, 3 parts of pilose antler blood powder and 1500 parts of white spirit;
more preferably, the white spirit is 53-degree white spirit.
The second purpose of the invention is to provide a method for preparing cordyceps guangdongensis medicinal liquor, which is obtained by putting cordyceps guangdongensis fruiting body powder and pilose antler blood powder into white spirit and soaking for more than one month.
Preferably, 15 parts by weight of the cordyceps guangdongensis sporophore powder, 3 parts by weight of the pilose antler blood powder and 1500 parts by weight of the white spirit are taken;
more preferably, the white spirit is 53-degree white spirit.
The third purpose of the invention is to provide the application of the Guangdong cordyceps sinensis medicinal liquor in the preparation of uric acid reducing products.
The Guangdong cordyceps sinensis is a novel food raw material which can be safely eaten and has rich nutrient components and active components. The invention provides Guangdong cordyceps medicinal liquor with the effect of reducing uric acid by taking Guangdong cordyceps as a raw material, which is prepared from Guangdong cordyceps fruiting body powder, pilose antler blood powder and white spirit. The results of animal experiments show that the effect of reducing uric acid is close to that of a clinical medicine allopurinol tablet. The medicinal liquor has good development and utilization prospects.
Drawings
FIG. 1 is a graph comparing the serum creatinine levels of various groups of mice.
FIG. 2 is a graph comparing the uric acid content in serum of mice in each group.
The specific implementation mode is as follows:
the following examples are further illustrative of the present invention and are not intended to be limiting thereof. The test methods in the following examples are all conventional test methods unless otherwise specified, and the test reagents and consumables described in the following examples are all available from conventional biochemical reagents company, unless otherwise specified.
Example 1 preparation of Cordyceps Guangdong medicated liquor
Micronizing dried Cordyceps guangdongensis fruiting body in clean environment, adding 15 weight parts of fruiting body powder into 3 weight parts of cornu Cervi Pantotrichum blood powder, placing in a sterilized sealed container, adding 53% Chinese liquor 100 times of the weight of Cordyceps guangdongensis fruiting body powder, soaking the powder, sealing the container, and storing at room temperature for 1 month to obtain Cordyceps guangdongensis medicated liquor.
Example 2 uric acid lowering effect of Guangdong Cordyceps sinensis medicated liquor
Mouse feeding conditions: SPF-grade KM mice 5/box, group rearing, rearing temperature and humidity: at the temperature of 22.2-22.9 ℃, 63.8-67.1%, adopting the following steps of 10 h: 14h day and night intermittent illumination; the condition of the feeding room is always kept stable to ensure the reliability of the test result. Free eating and drinking.
Grouping experiments: the SPF level male Kunming mice (KM mice) are randomly divided into a normal control group, a model group, a positive control group 1, a positive control group 2 and a Guangdong cordyceps sinensis medicinal liquor group according to body weight, and 10 mice/group. Gavage the normal control group and the model group of mice according to 0.2mL/10g of body weight and then give a sodium carboxymethylcellulose (CMC-Na) solution with the mass fraction of 0.5 percent; the positive control group 1 mice were administered 2mg/mL of allopurinol tablet solution daily by gavage at a dose of 40mg/kg/d BW at a rate of 0.2mL/10g body weight; the positive control group 2 mice were gavaged with the 'deer-two medicated wine' according to the weight of 0.075mL/10g each day, and the dosage was 7.5 mL/kg/dBW; the gavage amount of the Guangdong Cordyceps sinensis medicated wine (prepared in example 1) in the group is 7.5mL/kg/dBW according to the weight of 0.075mL/10 g. Each group of mice was given the corresponding solution at the corresponding dose volume for 1 day/time for 7 consecutive days.
Molding: 30min before the last administration, the animals of the normal control group are injected with 0.5% sodium carboxymethylcellulose (CMC-Na) solution with the same quantity into the abdominal cavity, and the other animals of each group are injected with 500mg/kg hypoxanthine solution into the abdominal cavity and 50mg/kg potassium oxonate solution into the subcutaneous cavity for molding.
And (3) experimental observation: observing animal hair, behavior, mental state, etc. from the beginning to the end of the experiment, and recording for 1 time every day; mice were weighed 1 time at 1, 3, 7d of the experiment.
And (3) biochemical index detection: after the animals in each group are administered for 30min at the last time, taking blood from eyeball, centrifuging at 3000rpm for 10min, and separating serum; livers were rapidly harvested and stored in liquid nitrogen. The activity of xanthine oxidase in serum and liver is detected by full-automatic biochemical analyzer for detecting the serum-to-white ratio (the ratio of plasma albumin ALB to globulin GLB), uric acid, creatinine and urea nitrogen levels of each group of mice and Xanthine Oxidase (XOD) test box.
The experimental results are as follows:
1) the conventional observation result shows that the hair color of the animal is bright, and abnormal secretions do not appear in the mouth, eyes, ears and nose; the excrement is not rotten, and the urine is clear and transparent; the body state, the hair, the mucosa, the autonomic activity and other manifestations are not abnormally changed.
2) During the administration period, the weight of each group of animals normally increased, and compared with the model group, the weight of the positive control group 1 and the Guangdong Cordyceps sinensis medicated wine group mice increased slowly compared with the model group, and the weight of the mice had statistical difference (P <0.05) (Table 1).
TABLE 1 influence of Cordyceps guangdongensis medicated liquor on body weight of experimental mice
Note: n represents the number of animals on the seventh day of gavage; "" indicates a significant difference P <0.05 compared to the normal control group.
3) White sphere ratio (A/G): the white ball ratio of the sera of the mice in each group was not statistically different (P > 0.05) (Table 2).
4) Urea nitrogen: compared with a normal control group, the urea nitrogen content of the serum of the model group mouse is obviously increased, and the statistical difference is realized (P is less than 0.01); the serum urea nitrogen levels of the remaining groups of mice were reduced compared to the model group, but no statistical differences were observed (P > 0.05) (Table 2).
TABLE 2 Biochemical index detection of uric acid lowering effect of Guangdong Cordyceps medicated liquor
Note: n represents the number of animals on the seventh day of gavage; "" x "indicates a significant difference P <0.01 from the normal control group," "Δ" indicates a significant difference P <0.05 from the model group, and "Δ" indicates a significant difference P <0.01 from the model group.
5) Creatinine: compared with a normal control group, the serum creatinine content of the model group mouse is obviously increased (P is less than 0.01); compared with the model group, the serum creatinine content of mice in the positive control group 1, the positive control group 2 and the Guangdong cordyceps sinensis medicated wine group is reduced significantly, and is statistically different (figure 1, "+" indicates that a very significant difference P <0.01, and "+" indicates that a very significant difference P < 0.05).
6) Uric acid: compared with the normal control group, the serum uric acid content of the model group mouse is obviously increased, has statistical difference (P is less than 0.01) which is about 5.4 times of that of the normal control group, and prompts that the model of the hyperuric acid mouse induced by intraperitoneal injection of 500mg/kg/d BW hypoxanthine solution and subcutaneous injection of 50mg/kg/d BW oxonate potassium solution is successfully molded. Compared with the model group, the serum uric acid content of mice in the positive control group 1, the positive control group 2 and the Guangdong cordyceps sinensis medicated wine group is remarkably reduced, and the mice have statistical difference (P is less than 0.01) (figure 2, "+" shows that the mice have extremely remarkable difference P is less than 0.01).
7) Liver XOD: compared with a normal control group, the liver XOD activity of the model group mice is increased, but no statistical difference is seen (P is more than 0.05); compared with the model group, the positive control group 1, the positive control group 2 and the Guangdong cordyceps sinensis medicated wine group all have reduced liver XOD activity, but no statistical difference (P is more than 0.05) is seen (Table 2).
8) Serum XOD: compared with a normal control group, the serum XOD activity of the model group mouse is obviously increased, and the statistical difference is realized (P is less than 0.05); the remaining mice showed a decrease in serum XOD activity compared to the model group, but no statistical differences (P > 0.05) were observed (Table 2).
In conclusion, the cordyceps guangdongensis medicinal liquor can reduce the content of uric acid and creatinine in serum of a mouse with high uric acid. Therefore, the Guangdong cordyceps sinensis medicinal liquor has the effect of reducing uric acid, and the effect of reducing uric acid is close to that of a positive control clinical medicament allopurinol tablet and a traditional medicinal liquor 'Luliangde'.
Claims (7)
1. A Cordyceps guangdongensis (Cordycepsguangdongensis) medicated liquor with uric acid lowering effect is characterized by comprising Cordyceps guangdongensis fruiting body powder, cornu Cervi Pantotrichum blood powder and Chinese liquor.
2. The Guangdong cordyceps sinensis medicinal liquor as claimed in claim 1, which is characterized by comprising 15 parts by weight of Guangdong cordyceps sinensis fruiting body powder, 3 parts by weight of pilose antler blood powder and 1500 parts by weight of white spirit.
3. The Guangdong cordyceps sinensis medicinal liquor as claimed in claim 1 or 2, wherein the white spirit is 53-degree white spirit.
4. A method for preparing Guangdong Cordyceps medicated liquor is characterized in that dried Guangdong Cordyceps sinensis fruiting bodies are subjected to superfine grinding and then are soaked in white spirit together with pilose antler blood powder for more than one month.
5. The method as claimed in claim 4, wherein the Cordyceps guangdongensis fruiting body powder is 15 parts by weight, the cornu Cervi Pantotrichum blood powder is 3 parts by weight, and the Chinese liquor is 1500 parts by weight.
6. The method according to claim 4 or 5, wherein the white spirit is 53-degree white spirit.
7. The use of the cordyceps guangdongensis medicated wine of claim 1, 2 or 3 in the preparation of uric acid reducing products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111288108.1A CN113975302A (en) | 2021-11-02 | 2021-11-02 | Guangdong cordyceps sinensis medicinal liquor for reducing uric acid and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111288108.1A CN113975302A (en) | 2021-11-02 | 2021-11-02 | Guangdong cordyceps sinensis medicinal liquor for reducing uric acid and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113975302A true CN113975302A (en) | 2022-01-28 |
Family
ID=79745788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111288108.1A Pending CN113975302A (en) | 2021-11-02 | 2021-11-02 | Guangdong cordyceps sinensis medicinal liquor for reducing uric acid and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113975302A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111454814A (en) * | 2019-10-10 | 2020-07-28 | 浙江泛亚保健食品有限公司 | Guangdong cordyceps wine |
| CN113546097A (en) * | 2021-07-21 | 2021-10-26 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia |
-
2021
- 2021-11-02 CN CN202111288108.1A patent/CN113975302A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111454814A (en) * | 2019-10-10 | 2020-07-28 | 浙江泛亚保健食品有限公司 | Guangdong cordyceps wine |
| CN113546097A (en) * | 2021-07-21 | 2021-10-26 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | Application of ethanol extract of cordyceps guangdongensis fruiting body in preparation of medicine for preventing obesity and hyperlipidemia |
Non-Patent Citations (3)
| Title |
|---|
| 尹艳艳: "蛹虫草对高尿酸患者降尿酸作用的病例分析", 《时珍国医国药》 * |
| 范玲: "《痛风吃什么宜忌速查》", 31 January 2014 * |
| 黄虹: "广东虫草安全性评价及药理学研究进展", 《菌物研究》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Evans et al. | Effect of pseudo-cholinesterase level on action of succinylcholine in man | |
| US4735967A (en) | Method for desensitizing the gastrointestinal tract from food allergies | |
| CN113274481B (en) | Composition for regulating blood sugar and preparation method and application thereof | |
| CN114259507A (en) | Application of Klebsiella minutissima in preparing medicine for treating and/or preventing hyperuricemia-related diseases | |
| CN113975302A (en) | Guangdong cordyceps sinensis medicinal liquor for reducing uric acid and preparation method and application thereof | |
| Root et al. | Absorption of insulin labeled with radioactive iodine in human diabetes | |
| Taylor et al. | Quinidine-Induced Exfoliative Dermatitis: With a Brief Review of Quinidine Idiosyncrasies | |
| CN108653298A (en) | Monosaccharide composition, pharmaceutical preparation and its application | |
| CN101904856A (en) | Application of 1,6-diphosphofructose and derivative thereof in preparing animal medical health care products | |
| JP2019210269A (en) | Composition for treating diabetic disease | |
| TW202308617A (en) | Anti-anxiety composition | |
| Richter et al. | Action of Human “Pernicious Anemia Liver Extract.” | |
| Morrison et al. | Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis | |
| CN108379455B (en) | Uric acid reducing composition | |
| Towiwat et al. | Effect of caffeinated and decaffeinated coffee on serum uric acid and uric acid clearance, a randomised within-subject experimental study | |
| Gotthard et al. | Effect of cimetidine and oxmetidine on 24-h gastric acid and pepsin in patients | |
| TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver | |
| CN114177163B (en) | Medicine for treating hypertension | |
| US20030118663A1 (en) | Method and composition for treating diabetes | |
| US20230310556A1 (en) | Prevention and treatment of diseases using phytase | |
| US4082842A (en) | Medicant composition for the treatment of diabetes | |
| Shemyakova et al. | Comparative Characteristics of Treatment Methods in Dogs Isosporosis and Giardiasis. | |
| CN112674346A (en) | Natural health-care composition for reducing high blood pressure, high blood sugar and high blood lipid as well as preparation method and application thereof | |
| Tang et al. | Use of enteral nutrition and factors influencing feeding intolerance in severely ill patients in the intensive care unit | |
| TWI664972B (en) | Fermented antrodia cinnamomea mycelia formulation and its application for heavy metal balance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220128 |
|
| RJ01 | Rejection of invention patent application after publication |